Last updated September 10, 2026
Key finding
Occurrence of GDM was significantly lower in the DCI group compared to that in placebo group (24.8% vs. 38.1%, p = 0.027).
D-chiro inositol supplementation significantly reduced the occurrence of gestational diabetes in high-risk pregnant women compared to placebo.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Short-Term (≤3 mo)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
D-chiro inositol supplementation significantly reduced the occurrence of gestational diabetes in high-risk pregnant women compared to placebo.
Gestational diabetes can lead to complications for both mother and child, including increased risks during delivery and long-term health issues. By demonstrating that D-chiro inositol supplementation can significantly reduce the incidence of GDM, this study provides a potential preventive strategy for high-risk pregnant women, which could improve maternal and neonatal outcomes.
The study did not measure long-term outcomes related to maternal and infant health. Sample size and population characteristics may limit generalizability. No significant differences were found in fasting plasma glucose or 2-hour glycemia.
Published in
Publication details and source links for this paper.
Xinning C, Zhimei D, Zhanwei Z, Danqing C. D-chiro inositol supplementation reduces gestational diabetes occurrence in high-risk pregnant women. Food Science & Nutrition. 2024;13(1):e4601. doi:10.1002/fsn3.4601
D-chiro inositol supplementation reduced GDM occurrence to 24.8% compared to 38.1% in the placebo group (p = 0.027).
1-hour glycemia during OGTT was significantly lower in the D-chiro inositol group (8.35 ± 1.55 vs. 8.81 ± 1.85, p = 0.043).
Mean birth weight of newborns was significantly lower in the D-chiro inositol group (3341.6 ± 420.1 g vs. 3487.9 ± 437.7 g, p = 0.011).
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Myo-inositol supplementation and 1-Hour Glycemia Change, 2-hour plasma glucose, Fasting Plasma Glucose (FPG), and 2 more.
This study contributes evidence to
Primary intervention
Myo-inositol supplementation
Primary outcomes
Primary intervention
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
4
Related topics
5
Evidence pairs
982
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence topic
matched_outcome
Related evidence
Evidence topic
Save evidence
Core evidence
The primary outcomes reported in this study.
Myo-inositol supplementation → 1-Hour Glycemia Change
Myo-inositol supplementation → 1-Hour Glycemia Change
Myo-inositol supplementation → 2-hour plasma glucose
Myo-inositol supplementation → 2-hour plasma glucose
Myo-inositol supplementation → Fasting Plasma Glucose (FPG)
Myo-inositol supplementation → Fasting Plasma Glucose (FPG)
Myo-inositol supplementation → Gestational diabetes mellitus incidence
Myo-inositol supplementation → Gestational diabetes mellitus incidence
Myo-inositol supplementation → Neonatal birth weight
Myo-inositol supplementation → Neonatal birth weight
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Myo-inositol supplementation and Postprandial and OGTT Glucose, Myo-inositol supplementation and Fasting Glucose.
This study contributes to the evidence on the following intervention-outcome relationships.
Curated evidence collections and hubs this study is part of.
All studies measuring Fasting Glucose
Measures Fasting Glucose as a key outcome.
All studies on Myo-inositol supplementation
Contributes to Myo-inositol supplementation evidence base.
All studies measuring Postprandial and OGTT Glucose
Measures Postprandial and OGTT Glucose as a key outcome.
All studies measuring Neonatal birth weight
Measures Neonatal birth weight as a key outcome.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
2 results
2 results
2 results
2 results
2 results
Generated from the study's connected evidence using Evidence Intelligence™.
Myo-inositol supplementation may improve fasting plasma glucose (FPG).
ConsistencyScore™: Results are mixed and should be interpreted cautiously.
Ranked evidence signals
Fasting Plasma Glucose (FPG)
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | moderate positive | ConsistencyScore™ Mixed | 1 study
Why this answer: This answer is cautious because the available studies report mixed findings.
Limitations
Myo-inositol supplementation may reduce gestational diabetes mellitus incidence.
ConsistencyScore™: Results are mixed and should be interpreted cautiously.
Ranked evidence signals
Gestational diabetes mellitus incidence
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | moderate positive | ConsistencyScore™ Mixed | 1 study
Why this answer: This answer is cautious because the available studies report mixed findings.
Limitations
Current evidence does not show a clear benefit of Myo-inositol supplementation for 2-hour plasma glucose.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
2-hour plasma glucose
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | neutral | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Myo-inositol supplementation appears to improve 1-hour glycemia change.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
1-Hour Glycemia Change
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Follow the topics this study contributes to.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
